▲ Peaking
Business
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline with a $2.2 billion acquisition of autoimmune biotech firm Forte Biosciences.
Immunology
6 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Health
🔮 fades ✓
Breakdown of immune cells' interaction is key driver in aging, study finds
New research identifies the breakdown of immune cell communication as a primary driver of systemic aging.
◼ Archived
Health
🔮 fades ✓
Biologists pinpoint how common virus triggers multiple sclerosis
New biological research identifies specific Epstein-Barr virus components linked to the development of multiple sclerosis.
◼ Archived
Health
🔮 fades ✓
The First AI‑Designed Vaccine Has Been Tested in People. Here’s What Happened.
Clinical trials for the world's first AI-designed vaccine have entered human testing, marking a potential shift in medical development methodology.
◼ Archived
Health
🔮 fades ✓
Prime-and-pull vaccine may offer lasting genital herpes protection
A novel vaccine approach may soon offer long-term protection against genital herpes
◼ Archived
Business
🔮 fades ✓
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.